Oral Versus Intramuscular Cobalamin Treatment In Megaloblastic Anemia: A Single-Center, Prospective, Randomized, Open-Label Study by Bianco, Tiara & Wironen, John
RESEARCH POSTER PRESENTATION TEMPLATE © 2019
www.PosterPresentations.com
Presented By: Tiara Bianco and John Wironen
Zahit Bolaman, MD, Gurhan Kadikoylu, MD, Vahit Yukselen, MD, Irfan Yavasoglu, MD, Sabri 
Barutca, MD, and Taskin Senturk, MD
Oral Versus Intramuscular Cobalamin Treatment in Megaloblastic Anemia: A Single-
Center, Prospective, Randomized, Open-Label Study
Introduction
Purpose
Results
Conclusions
References
The prevalence of Vitamin B12 deficiency is 
between 8 and 16% in adults between the ages of 
24 and 64 years and higher in the elderly.2 The 
serious clinical sequalae of long-term vitamin B 
deficiency, include neurocognitive changes,3 
paresthesia, numbness and gait problems.4 If the 
deficiency continues for an extended period of 
time, these changes can be permanent and 
debilitating.5 Given these serious consequences, it 
is essential that practitioners effectively treat 
patients with this deficiency. 
The standard of care for vitamin B12 deficiency is 
to provide monthly intramuscular injections of 
cobolamin.6 However, this method has several 
drawbacks, including requiring clinic 
appointments, travel by the patient, time 
commitments, and associated expenses. An 
alternative treatment that allowed home care 
could provide the dual benefits of improved cost-
effectiveness and greater convenience.
In this single-center, prospective, randomized, 
open-labeled study, the cheapest and most 
effective treatment for megaloblastic anemia 
resulting from a cobalamin deficiency was 
investigated. This article compared the use of 
intramuscular injections to the oral administration 
of cyanocobalamin in 70 patients over 90 days, 
comparing both effectiveness and cost. From this 
the authors concluded that oral cobalamin 
treatment was equally effective at treating vitamin 
B12 deficiency as intramuscular injections. They 
also concluded that oral therapy was less 
expensive and better tolerated.
The purpose of this study was to compare the 
treatments of PO versus IM cobalamin for 
patients with megaloblastic anemia due to a 
cobalamin deficiency in terms of cost and 
effectiveness. 
From these results it can be concluded that PO 
cobalamin treatment is as effective as IM 
cobalamin treatment when treating patients with 
metaplastic anemia due to a cobalamin 
deficiency. It was also determined that the PO 
treatment was more tolerated and less expensive 
in comparison to the IM treatment costing $80 
oppose $220, respectively.  Within this study there 
were many strengths including that it was done 
simply to investigate the possibility of 
administering B12 orally, the authors, as a result, 
present as being unbiased.  Another strength of 
this article was its design employed block 
randomization and had statistically similar control 
and test groups, making the outcomes, as far as 
statistically possible, reliable. The study also had 
many weaknesses including is limited sample size 
(60 people) with 30 or fewer in the control and 
treatment groups.  Additionally, due to lack of 
available standardized dosage forms, liquid 
vitamin B12 was mixed with fruit juice to 
administer the PO dosage, which may have 
skewed the results of this study. Future studies 
should be performed and focus on using 
commercially available preparations of B12 that 
can be standardized and easily administered in a 
multi-center clinical trial.  Also, the number of 
patients enrolled needs to be much larger than 
any of the previous studies have been able to 
muster.
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Treatment 1000-
µg of cobalamin
• PO Group
• IM Group
First 10 days
• Once Daily
After 10 days to 
4 weeks
• Once Weekly
After 4 weeks for 
Life
• Once Monthly
PO Group
• n = 26
• Age
• Mean: 60
• Range: 32-84
• Sex
• Men: 16
• Women: 10
IM Group
• n = 34
• Age
• Mean: 64
• Range: 36-87
• Sex
• Men: 17
• Women: 17
Patient Demographics Methods (Cont.)
Patients were exclude from this study if they were 
vomiting and/or had diarrhea, alcohol use greater 
than 40 g/d, inability to provide informed consent, 
history of malignancy, folate deficiency, inability to 
ingest oral medication, pregnant or breastfeeding, 
and using a medication that would interfere with 
folate metabolism such as methotrexate or 
colchicine. The patients were assigned using 
block randomized study to be a part of the PO 
group or IM group receiving 1000-µg cobalamin 
once daily for the first ten days, followed by once 
weekly for four weeks, and then once monthly for 
life.  To ensure the success of the treatment the 
patients were assessed for reticulocytosis until it 
was detected between days five and ten of 
treatment. In order to determine therapeutic 
effectiveness, on days 0, 10, 30, and 90 
hematologic parameters were measured as well 
as serum vitamin B12 concentrations on days 0 
and 90. Laboratory tests of serum potassium 
levels and eosinophilia blood smears as well as 
patient interviews were conducted by 
Hematologists on days 0, 30, and 90 to determine 
tolerability of both treatment options. The authors 
compared the cost of the study drug and of the 
injections. Wilcoxon and Mann-Whitney U 
statistical analysis tests were used to compare 
the oral and parenteral treatment arms. 2-paired t 
test were used to compare pretreatment and 
posttreatment values. Lastly, the nominal 
variables were compared using the Yates chi-
square test and the p values were considered to 
be statistically significant at <0.05. Funding 
source not stated in article.  
Methods
Sixty patients over the age of 16 with with a serum 
cobalamin concentration less than 160 pg/mL, 
megaloblastic anemia due to a cobalamin deficiency, 
and a mean corpuscular volume greater than 94 fL
participated in a 90 day, prospective, randomized, 
open-labeled study at the Division of Hematology, 
Department of Internal Medicine, Adnan Menderes 
University Research and Practice Hospital in Aydin, 
Turkey.  
